Paracentesis underutilized in patients with cirrhosis, ascites

Paracentesis underutilized in patients with cirrhosis, ascites

(HealthDay)—For patients admitted with diagnoses of cirrhosis and ascites, paracentesis is associated with decreased in-hospital mortality but is underutilized, according to a study published online Dec. 8 in the Journal of Gastroenterology and Hepatology.

John N. Gaetano, M.D., from the University of Chicago, and colleagues identified 31,614 adults, non-electively admitted with diagnoses of cirrhosis and ascites. Utilization and outcomes of paracentesis were examined.

The researchers found that 51 percent of the hospitalized patients underwent paracentesis. The overall in-hospital rate was 7.6 percent, with increased mortality seen among patients who did not versus those who did undergo paracentesis (8.9 versus 6.3 percent; P < 0.001). In-hospital mortality was 1.83-fold higher for patients who did not receive paracentesis versus those who did receive paracentesis. There was a reduction in mortality for early paracentesis versus late paracentesis (5.5 versus 7.5 percent). Less frequent use of early paracentesis was seen for patients admitted on a weekend (50 versus 62 percent for those admitted on a weekday; adjusted odds ratio, 1.12). Early paracentesis correlated with shorter length of stay and decreased hospitalization costs among diagnosed with spontaneous bacterial peritonitis (both P < 0.001).

"[These data support] the use of paracentesis as a key inpatient quality measure among hospitalized adults with ," the authors write. "Future studies are needed to investigate the barriers to paracentesis use on admission."

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Paracentesis underutilized in patients with cirrhosis, ascites (2015, December 11) retrieved 24 April 2024 from https://medicalxpress.com/news/2015-12-paracentesis-underutilized-patients-cirrhosis-ascites.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Study shows potential of anti-growth factor drugs for reducing complication of advanced ovarian cancer

0 shares

Feedback to editors